7 results about "Rhodopsin" patented technology

The disclosure relates to a fusion protein including a transcription enhancer and a dCas9 protein, a complex for epigenetic regulation including the fusion protein and one or more guide RNAs (gRNAs), etc.The fusion protein or complex according to an aspect may induce apoptosis of colorectal cancer cells or compensate for rhodopsin deficiency by activating the gene EGFL8, opsin mw, etc., and may be utilized as a pharmaceutical composition or the like for preventing or treating cancer or ocular diseases.

Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

The invention discloses a visual purple protein maximum absorption light wavelength prediction method based on a graph neural network. Comprising the following steps: generating a three-dimensional structure model according to an amino acid sequence of a to-be-predicted rhodopsin protein; generating a ligand pocket graph according to the three-dimensional structure model of the visual purple protein to be predicted; and inputting the ligand pocket graph into a pre-trained maximum absorption wavelength prediction model to obtain a maximum absorption wavelength prediction value. The method can make full use of protein three-dimensional structure information, accurately characterizes the ligand binding pocket microenvironment, has high prediction precision and strong generalization ability, and has important scientific significance and application value.

A quantum dot (QD)-rhodopsin bioconjugate system uses Förster resonance energy transfer (FRET)-mediated induction of cellular membrane depolarization via optical activation of ion channel proteins channelrhodopsin (ChR).

Described herein are pharmacologic correctors of rhodopsin, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating disease.

Described herein are pharmacologic correctors of rhodopsin, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating disease.

A method of treating a retinal disease in a subject in need thereof, the method comprising administering to the subject a vector that comprises a mirtron for knocking down expression of a target gene expressed in the retina and a gene therapy vector comprising a mirtron for rhodopsin knock-down.